The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Immune checkpoint inhibitors have been shown to increase survival in metastatic solid tumor patients when compared to the previously standard of care chemotherapy. Epidemiologic studies of American Indian cancer patients demonstrated having significantly worse survival when compared with Caucasians when controlled for age, sex, alcohol abuse, smoking, insurance, and disease stage. There are no current studies specifically examining the American Indian population receiving treatment with immune checkpoint inhibitors. The aim is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Study Type
OBSERVATIONAL
Enrollment
72
immunotherapy
Arizona Cancer Center at the Unvieristy of Arizona
Tucson, Arizona, United States
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Monument Health Cancer Care Institute
Rapid City, South Dakota, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States
Progression Free Survival
Evaluating progression free survival of American Indian population vs. White population who were treated with immunotherapy
Time frame: 1 year
Overall Survival Benefit
Evaluating the overall survival benefit of American Indian population vs. white population who were treated with immunotherapy
Time frame: 1 year
Treatment related Adverse Events
Evaluating treatment related adverse events of American Indian population vs. white population who were treated with immunotherapy
Time frame: 1 year
Difference in cancer related mortality
Evaluate the difference in cancer related mortality in American Indian populations vs white
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.